HLB Life Science CO.,LTD. Logo

HLB Life Science CO.,LTD.

Develops anti-cancer drugs and distributes IVD medical devices and lab supplies internationally.

067630 | KO

Overview

Corporate Details

ISIN(s):
KR7067630004
LEI:
Country:
South Korea
Address:
경기도 화성시 동탄첨단산업1로 51-9 8층(영천동,엠타워지식산업센터), 화성시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

HLB Life Science Co., Ltd. is a specialized pharmaceutical and biotechnology firm operating with a dual focus. The company is dedicated to the development of innovative and differentiated anti-cancer medications as part of the broader HLB Group's global oncology strategy. Concurrently, its Medicare business develops, manufactures, and distributes a range of products including in-vitro diagnostic (IVD) medical devices, quasi-drugs, research reagents, and laboratory supplies. The company serves both domestic and international markets, providing healthcare solutions that span from diagnostics to therapeutics.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-13 00:00
Interim Report
반기보고서 (2025.06)
Korean 2.0 MB
2025-08-01 00:00
M&A Activity
[기재정정]주요사항보고서(회사합병결정)
Korean 56.6 KB
2025-08-01 00:00
M&A Activity
기타주요경영사항 (회사 합병결정 철회)
Korean 4.1 KB
2025-07-10 00:00
Post-Annual General Meeting Information
임시주주총회결과
Korean 7.1 KB
2025-06-19 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 141.4 KB
2025-06-19 00:00
Proxy Solicitation & Information Statement
의결권대리행사권유참고서류
Korean 110.7 KB
2025-05-29 00:00
Capital/Financing Update
전환가액의조정 (제13회차)
Korean 10.7 KB
2025-05-19 00:00
M&A Activity
[기재정정]주요사항보고서(회사합병결정)
Korean 81.4 KB
2025-05-19 00:00
Pre-Annual General Meeting Information
[기재정정]주주총회소집결의
Korean 12.5 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.9 MB
2025-04-15 00:00
Delisting Announcement
기타시장안내 (에이치엘비생명과학 9WR 신주인수권 행사기간 만료 및 상장폐지 예고)
Korean 3.4 KB
2025-04-10 00:00
Related Party Transaction
임원ㆍ주요주주특정증권등거래계획철회보고서
Korean 16.1 KB
2025-04-10 00:00
Share Issue/Capital Change
전환가액의조정 (제14회차)
Korean 10.3 KB
2025-04-08 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 83.0 KB
2025-04-07 00:00
Capital/Financing Update
전환가액의조정 (제11회차)
Korean 12.0 KB

Automate Your Workflow. Get a real-time feed of all HLB Life Science CO.,LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for HLB Life Science CO.,LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for HLB Life Science CO.,LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

REGENXBIO Inc. Logo
Developing AAV gene therapies for retinal, metabolic, and neurodegenerative diseases.
United States of America
RGNX
Rein Therapeutics, Inc. Logo
Clinical-stage biopharma developing novel therapies for orphan pulmonary diseases and fibrosis.
United States of America
RNTX
Rekah Pharmaceutical Prod Ltd. Logo
A full-service generic pharma manufacturer of drugs, devices, and supplements for global markets.
Israel
REKA
Relay Therapeutics, Inc. Logo
Developing precision medicines for oncology & genetic diseases by analyzing protein motion.
United States of America
RLAY
Repare Therapeutics Inc. Logo
Develops precision oncology drugs using a CRISPR platform for cancers with genomic instabilities.
United States of America
RPTX
Replek AD Logo
Manufactures & distributes generic medicines, supplements, and cosmetic products to over 25 countries.
North Macedonia
REPL
Respiratorius AB Logo
Develops oncology pre-treatment drugs to enhance the efficacy of standard cancer therapies.
Sweden
RESP
REVELATION BIOSCIENCES, INC. Logo
Develops therapies that reprogram the innate immune system to reduce inflammation-related damage.
United States of America
REVB
REVIVA PHARMACEUTICALS HOLDINGS, INC. Logo
Clinical-stage biopharma developing novel therapies for CNS, respiratory, and metabolic diseases.
United States of America
RVPH
Revolution Medicines, Inc. Logo
A clinical-stage oncology company developing targeted therapies for RAS-addicted cancers.
United States of America
RVMD

Talk to a Data Expert

Have a question? We'll get back to you promptly.